Cyclooxygenase-2 expression is associated with chemoresistance through cancer stemness property in hypopharyngeal carcinoma.
cancer stemness
chemoresistance
cyclooxygenase-2
head and neck cancer
hypopharyngeal carcinoma
prostaglandin E receptor 2
Journal
Oncology letters
ISSN: 1792-1074
Titre abrégé: Oncol Lett
Pays: Greece
ID NLM: 101531236
Informations de publication
Date de publication:
Jul 2021
Jul 2021
Historique:
received:
15
01
2021
accepted:
20
04
2021
entrez:
4
6
2021
pubmed:
5
6
2021
medline:
5
6
2021
Statut:
ppublish
Résumé
Cyclooxygenase-2 (COX-2) is one of the two isoforms of COX, an enzyme that catalyzes the conversion of arachidonic acid to prostaglandins. COX-2 is associated with the progression in various types of cancer, and its expression has been associated with a poor prognosis in head and neck squamous cell carcinoma (HNSCC). Furthermore, COX-2 expression has been associated with resistance to anticancer drugs. However, the precise mechanism of COX-2 for chemoresistance in HNSCC has not been fully elucidated. The present study aimed to investigate the effect of COX-2 on cancer stem cell (CSC) property and to reveal its effect on chemoresistance using
Identifiants
pubmed: 34084214
doi: 10.3892/ol.2021.12794
pii: OL-0-0-12794
pmc: PMC8161457
doi:
Types de publication
Journal Article
Langues
eng
Pagination
533Informations de copyright
Copyright: © Saito et al.
Déclaration de conflit d'intérêts
The authors declare that they have no competing interests.
Références
Cancer Invest. 2013 Feb;31(2):97-102
pubmed: 23245395
Anticancer Res. 2004 Sep-Oct;24(5A):2723-8
pubmed: 15517878
Childs Nerv Syst. 2010 Nov;26(11):1605-12
pubmed: 20526717
Int J Oncol. 2013 May;42(5):1833-41
pubmed: 23525457
Acta Oncol. 2018 Feb;57(2):244-250
pubmed: 29140138
Medicine (Baltimore). 2015 Nov;94(44):e1806
pubmed: 26554780
Nanomedicine (Lond). 2012 Apr;7(4):597-615
pubmed: 22471722
Oral Oncol. 2009 Oct;45(10):e124-8
pubmed: 19457709
Oncogene. 2017 Jun 1;36(22):3137-3148
pubmed: 27941877
Ann Surg Oncol. 2011 Oct;18(10):2946-51
pubmed: 21437756
Cancer Metastasis Rev. 2018 Sep;37(2-3):355-368
pubmed: 30094570
Sci Rep. 2016 Sep 22;6:33823
pubmed: 27654511
Nat Med. 2011 Jul 03;17(7):860-6
pubmed: 21725296
Nat Rev Clin Oncol. 2020 Apr;17(4):204-232
pubmed: 31792354
Am J Transl Res. 2020 Mar 15;12(3):1096-1113
pubmed: 32269737
Laryngoscope. 2008 Aug;118(8):1362-71
pubmed: 18496152
Int J Oncol. 2009 Mar;34(3):847-52
pubmed: 19212690
Clin Ther. 2014 Aug 1;36(8):1253-63
pubmed: 25016505
Int J Cancer. 2006 Jan 15;118(2):396-404
pubmed: 16052515
Oncotarget. 2017 Jul 6;8(35):59950-59964
pubmed: 28938696
Head Neck. 2008 Sep;30(9):1175-81
pubmed: 18642283
Stem Cells. 2016 Sep;34(9):2290-305
pubmed: 27301070
Cancer Prev Res (Phila). 2009 Sep;2(9):823-9
pubmed: 19737986
Mol Cancer Res. 2010 Oct;8(10):1310-8
pubmed: 20858737
J Biol Chem. 2008 Apr 25;283(17):11155-63
pubmed: 18319253
J Clin Oncol. 2008 Jun 10;26(17):2871-5
pubmed: 18539966
Oncotarget. 2016 Jul 26;7(30):47265-47277
pubmed: 27323811
Laryngoscope. 2021 May;131(5):E1543-E1549
pubmed: 33098325
Hum Pathol. 2002 Jul;33(7):708-14
pubmed: 12196922
J Biol Chem. 2002 Oct 11;277(41):38915-20
pubmed: 12138126
Int J Oncol. 2018 Sep;53(3):1138-1148
pubmed: 29956730
Anticancer Res. 2019 Oct;39(10):5623-5630
pubmed: 31570459
Int J Radiat Oncol Biol Phys. 2005 Oct 1;63(2):520-8
pubmed: 16168844
Nat Rev Cancer. 2008 Oct;8(10):755-68
pubmed: 18784658
Oral Oncol. 2010 Dec;46(12):880-7
pubmed: 20951077
Oncoimmunology. 2012 Aug 1;1(5):762-764
pubmed: 22934275
J Exp Med. 2003 Jan 20;197(2):221-32
pubmed: 12538661
J Cancer Res Ther. 2011 Oct-Dec;7(4):442-7
pubmed: 22269407
Oral Oncol. 2003 Dec;39(8):829-35
pubmed: 13679206
Drug Discov Today. 2017 Jan;22(1):57-71
pubmed: 27506873
Oncotarget. 2017 Jul 17;8(47):82217-82230
pubmed: 29137258
N Engl J Med. 2005 Mar 17;352(11):1071-80
pubmed: 15713944
J Clin Oncol. 2017 Jul 1;35(19):2184-2192
pubmed: 28489511
Oncotarget. 2017 Dec 14;8(70):115254-115269
pubmed: 29383157
Cancer Res. 1999 Mar 1;59(5):991-4
pubmed: 10070952
Br J Pharmacol. 2011 Dec;164(7):1847-56
pubmed: 21595651
J Exp Clin Cancer Res. 2014 May 10;33:40
pubmed: 24887090
Oral Oncol. 2016 May;56:54-61
pubmed: 27086487
Clin Cancer Res. 2007 May 15;13(10):3015-23
pubmed: 17505004
Br J Pharmacol. 2015 Nov;172(22):5239-50
pubmed: 26377664
Oncotarget. 2016 May 10;7(19):28235-46
pubmed: 27058422